EUVIMEDScopri EUVIMED
Crossref

Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway

Yu Liao, Kejun Hu, Wangwang Liu, Wei Wang, Huanhuan Qiu, Shumin Pan, Qi Lv, Guanglin Xu iD

Basic & Clinical Pharmacology & Toxicology · 2023-04 · 132 (4) · 297-311

DOI: 10.1111/bcpt.13832 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, published online on 2023-01-15. Written by Yu Liao and 7 co-authors. Institution: College of Life Sciences, Nanjing Normal University, Nanjing, China. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms. Cited 8 times so far (Crossref); 27 references. Funded by: National Natural Science Foundation of China.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Hepatocellular carcinoma (HCC) is one of the principle causes of cancer‐associated death throughout the world. However, the patients with HCC are insensitive to traditional drugs and lack effective therapeutic drugs. Dysregulation of Hippo‐Yes‐associated protein (YAP) signalling is closely associated with HCC. Bortezomib (BTZ) is mainly used in clinical multiple myeloma. It has recently been confirmed that BTZ could suppress cell proliferation in many different types of cancer. Nevertheless, the precise effects of BTZ on HCC and its possible interactions with the Hippo‐YAP signalling pathway in HCC cells remain largely unknown. In this study, HCC cell lines (HepG2 and Huh7) and nude mice with xenograft tumours were used to evaluate the influences of BTZ. Furthermore, we focused on exploring whether BTZ exerts its anti‐HCC effect through the Hippo‐YAP signalling pathway and aimed to lay a theoretical foundation for BTZ as a potential therapeutic drug for HCC. Herein, our results disclose a new mechanism of BTZ in controlling the cell growth of HCC. BTZ downregulates the level of YAP by promoting LATS1 expression to inhibit the growth of HCC cells, which leads to the phosphorylation of YAP and limits YAP nuclear translocation. In sum, our data confirmed that the Hippo‐YAP signalling pathway mediates the anti‐HCC effects of BTZ.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMiceAnimalsHumansYAP-Signaling ProteinsBortezomibSignal TransductionMice, NudeCell Line, TumorTranscription FactorsCell Proliferation

Author keywords

LATS1YAPbortezomibhepatocellular carcinomaxenograft model

Substances

YAP-Signaling ProteinsBortezomibTranscription Factors

Authors and institutions

  • College of Life Sciences, Nanjing Normal University, Nanjing, China.
  • School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.

ORCID profiles: Guanglin Xu

Funding

  • National Natural Science Foundation of China

Cite

APA

Liao, Y., Hu, K., Liu, W., Wang, W., Qiu, H., Pan, S., Lv, Q., & Xu, G. (2023). Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway. Basic & Clinical Pharmacology & Toxicology, 132(4), 297-311. https://doi.org/10.1111/bcpt.13832

Vancouver

Liao Y, Hu K, Liu W, Wang W, Qiu H, Pan S, et al. Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway. Basic & Clinical Pharmacology & Toxicology. 2023;132(4):297-311. doi:10.1111/bcpt.13832

BibTeX
@article{Liao2023,
  author = {Liao, Yu and Hu, Kejun and Liu, Wangwang and Wang, Wei and Qiu, Huanhuan and Pan, Shumin and Lv, Qi and Xu, Guanglin},
  title = {Bortezomib inhibits hepatocellular carcinoma via the Hippo‐Yes‐associated protein signalling pathway},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2023},
  volume = {132},
  number = {4},
  pages = {297--311},
  doi = {10.1111/bcpt.13832}
}
Start for free →